Smoking Cessation and Nicotine Addiction Epidemiolog

Key Highlights

• Most Smoking Cessation and Nicotine Addiction patients were estimated in the US, followed by EU4 and the UK, and Japan.
• In 2022, the total number of Smoking Cessation and Nicotine Addiction in the 7MM accounted for 47 million cases. These cases are expected to decrease with a fall in the prevalence of tobacco use during the forecast period (2025-2034).
• Gender-specific prevalent cases of tobacco use were higher in males (around 31,414 thousand cases) compared to females (around 20,085 thousand) in 2022 in the 7MM.
• Among the age groups 18–24 years, 25–44 years, 45–64 years, and 65+ years, the highest number of tobacco users were estimated to be in the group 25–44 years, accounting for around 44% of the total tobacco users in the US in 2022.

DelveInsight’s “Smoking Cessation and Nicotine Addiction – Epidemiology – 2034” report delivers an in-depth understanding of Smoking Cessation and Nicotine Addiction, historical and forecasted epidemiology of Smoking Cessation and Nicotine Addiction in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Smoking Cessation and Nicotine Addiction Disease Understanding 

Smoking Cessation and Nicotine Addiction Overview

Nicotine/tobacco dependence is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated tobacco use and that typically include a strong desire to use tobacco, difficulties in controlling its use, persistence in tobacco use despite harmful consequences, a higher priority given to tobacco use than other activities and obligations, increased tolerance and sometimes a physical withdrawal state.

The main source of nicotine is tobacco. The main administration means smoking pipes/cigars, chewing, and snorting fine powders. Cigarette smoking is most common both in terms of prevalence and health consequences.

Major causes of nicotine addiction include lack of enforcement of smoking bans, lack of proper knowledge and education on the topic (mostly in underdeveloped countries), lack of motivation to quit smoking, inadequate training among mental health professionals, and inadequate treatments. Habitual use of tobacco and tobacco products contributes significantly to health problems worldwide.

Smoking Cessation and Nicotine Addiction Diagnosis

Repeated exposure to nicotine develops neuroadaptation of the receptors, resulting in tolerance to many of the effects of nicotine. Withdrawal symptoms appear on stoppage of tobacco use, characterized by irritability, anxiety, increased eating, dysphoria, and hedonic dysregulation, among others. Smoking is also reinforced by conditioning.

Metabolites of nicotine such as cotinine, nornicotine, and anabasine can be detected in urine and blood; these tests can test compliance with withdrawal therapy or nicotine toxicity. Another method to assess nicotine is COa level; this method is related to cotinine. Some questionnaires can measure nicotine dependence, such as the Fagerstrom Test for Nicotine Dependence, the Wisconsin Inventory of Smoking Dependence and Motives, and the Smokeless Tobacco Dependence Scale.

Further details related to diagnosis are provided in the report…

Smoking Cessation and Nicotine Addiction Epidemiology

As the market is derived using patient-based model, the Smoking Cessation and Nicotine Addiction epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by Prevalent Cases of tobacco use, Gender-specific prevalent cases of tobacco use, Age, Specific, prevalent cases of tobacco use, Prevalent cases of tobacco use by product type, and Prevalent nicotine dependent cases among cigarette smokers in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain), and the UK, and Japan from 2021 to 2034.

• The total number of prevalent cases of tobacco use in the US was the highest among the 7MM, comprising  51,499 thousand cases in 2022, and is projected to decrease during the forecast period (2025-2034). 
• Among the EU4 and the UK, Germany had the highest prevalent cases of tobacco use (18,353 thousand cases). On the other hand, the UK (9,004 thousand cases) had the lowest Prevalent Cases of Tobacco Use in EU4 and the UK countries and the 7MM.
• Of all the product types, tobacco smoking has been identified as a predominant smoking form; in our analysis, Smoking tobacco was higher than smokeless tobacco. In 2022, 90% of cases of tobacco users were Smoking tobacco, while 10% of cases were contributing to Smokeless tobacco in the United States.
• Out of total Cigarette Smokers, Nicotine Dependence was seen among 61% of cases in the United States.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Smoking Cessation and Nicotine Addiction evolving treatment landscape, patient reliance on conventional therapies, patient’s therapy switching acceptability, drug uptake, along with challenges related to accessibility, including HCPs, Physicians, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers such as the Johns Hopkins University, University Hospital Heidelberg, Université Paris-VII (Paris Diderot), etc., were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Smoking Cessation and Nicotine Addiction market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

• The report covers a segment of key events, an executive summary, and a descriptive overview of Smoking Cessation and Nicotine Addiction. It explains its Etiology and Risk factors, Clinical Manifestations, and current diagnosis and guidelines.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and diagnostic guidelines has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Smoking Cessation and Nicotine Addiction Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Gender-wise Cases of Smoking Cessation and Nicotine Addiction
• Age-wise Cases of Smoking Cessation and Nicotine Addiction
• Prevalent Cases of Tobacco use by Product Type
• Prevalent nicotine-dependent Cases Among Cigarette Smokers
• Prevalent Cases of Smoking Cessation

Smoking Cessation and Nicotine Addiction Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage 
• Smoking Cessation and Nicotine Addiction Epidemiology Segmentation

Smoking Cessation and Nicotine Addiction Report Assessment

• Current Diagnostic Regimen

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs related to Smoking Cessation and Nicotine Addiction? What will be the growth across the 7MM concerning the patient population with Smoking Cessation and Nicotine Addiction?
• What is the historical and forecasted Smoking Cessation and Nicotine Addiction patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why are region-based differences in the prevalence rate of the disease?
• Why is the distribution of tobacco users by product type and region-specific differences? 
• Which gender has a higher prevalence of tobacco use?
• Which age group has a higher prevalence of tobacco use?
• What is the distribution of nicotine dependence among cigarette smokers?

Reasons to Buy

• To understand the age-specific tobacco users in varying geographies over the coming years.
• A detailed overview of gender-specific and product-type tobacco users and the smoking cessation pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
• To understand smoking and smokeless tobacco users among the total patient pool.